SteelPeak Wealth LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,437 shares of the biopharmaceutical company's stock after selling 29,749 shares during the period. SteelPeak Wealth LLC's holdings in Gilead Sciences were worth $11,025,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. One Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 34.8% in the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company's stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Ariel Investments LLC boosted its holdings in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 109 shares in the last quarter. Covea Finance boosted its holdings in shares of Gilead Sciences by 69.5% in the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock valued at $5,732,000 after acquiring an additional 21,200 shares in the last quarter. Finally, Swedbank AB boosted its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock valued at $237,393,000 after acquiring an additional 16,663 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Performance
Shares of GILD opened at $113.58 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $140.93 billion, a P/E ratio of 22.63, a PEG ratio of 0.77 and a beta of 0.34. The company has a 50-day moving average of $114.36 and a two-hundred day moving average of $110.01. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's payout ratio is presently 62.95%.
Analyst Ratings Changes
A number of research firms recently commented on GILD. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a report on Saturday, September 27th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Finally, UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $117.17.
Check Out Our Latest Research Report on Gilead Sciences
Insider Buying and Selling at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by insiders.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
